Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Immix Biopharma, Inc.NASDAQ: IMMX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $575.57K fell 33.7% year over year, behind the -27.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +57.6% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.7% toward the trailing-twelve-month pace of -27.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$575.57K+0.8% QoQ
Last fiscal yearDec 2025
$2.44M-19.2% YoY
LTMMar 2026
$2.15M-27.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.7%——
1 year-19.2%——
3-year CAGR+57.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.44M USD
Year-over-year change
-19.2%
4-year CAGR
+82.7%

Stock-Based Compensation vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.0% is the 8th highest of 11, against a peer median of +0.2%.
  • Over three fiscal years its annual growth of +57.6% compares with a peer median of -5.2%.
IMMX Competitors
Stock-Based Compensation for IMMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-6.0%-2.6%53.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M USD-0.7%—32869.6%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥26.02M CNY+1.1%-74.4%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
IMUXImmunic, Inc.LTM Mar 2026$11.29M USD+44.4%+3.8%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$9.12M USD+17.3%-21.7%25.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M USD-27.0%+57.6%—
IMMPImmutep LimitedFY2025A$1.16M AUD-35.2%-7.8%23.1%
ABVXAbivax S.A.FY2025€0 EUR-100.0%——
Peer median (excluding IMMX) —+0.2%-5.2%25.6%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.38M)(8.23M)(15.6M)(21.61M)(29.44M)
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
Deferred Income Tax00000
Stock-Based Compensation218.98K624.07K2.57M3.02M2.44M
Change in Working Capital(391.04K)195.21K1.65M3.97M2.7M
Accounts Receivables97.67K(236.38K)(893.4K)(971.53K)2.06M
Inventory00000
Accounts Payables(106.06K)1.13M2.43M4.4M1.03M
Other Working Capital(382.64K)(700.15K)111.84K537.2K(384.74K)
Other Non-Cash Items22.96M002.94M0
Operating Cash Flow(1.59M)(7.41M)(11.37M)(14.6M)(23.93M)
Capital Expenditures(802)3(52.09K)(1.18M)(732.93K)
Acquisitions (Net)00000
Purchases of Investments0000(6.48M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(802)0(52.09K)(1.18M)(7.21M)
Debt Repayment200K(50K)000
Common Stock Issued18.65M3.39M15.7M15.95M107.39M
Common Stock Repurchased0(99.96K)000
Dividends Paid00000
Other Financing Activities0(6.72K)(232K)00
Financing Cash Flow18.85M3.23M15.46M15.95M107.39M
Effect of Forex Changes(5.43K)(31.52K)33.09K(3.62K)3.84K
Net Change in Cash17.25M(4.21M)4.07M172.16K76.25M
Free Cash Flow(1.59M)(7.41M)(11.42M)(15.77M)(24.66M)

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.